BRAF and neoplasm: BRAF inhibitors are currently used in the clinic against mutant BRAF melanomas; thus, we tested whether a combination strategy of SGI-1776 and the BRAF inhibitor PLX4720 could potentiate an anti-tumor response in a xenograft model featuring BRAF mutant 1205Lu cells, which are marginally responsive to PLX4720 [5].